Lisa C. Casey, William M. Lee
Curr Opin Gastroenterol. 2013;29(3):243-249.
Purpose of review: We review here the
recent literature regarding hepatitis C virus (HCV) therapy through
January 2013. We discuss current therapies, targets for new therapies,
and what might be expected in this rapidly changing field.
Recent findings: Boceprevir-based and
telaprevir-based triple therapy with pegylated interferon and ribavirin
marked the beginning of a new era in HCV therapy for genotype 1
patients. New direct-acting antivirals (DAAs) are being developed and
new antiviral drug targets are being explored. New combination treatment
regimens are expected to emerge soon and there is hope for
interferon-free regimens.
Summary: The standard of care for
treatment of HCV genotype 1 changed dramatically with the approval of
two new DAA drugs – telaprevir and boceprevir – for use in pegylated
interferon-based and ribavirin-based triple therapy in mid-2011.
Experience has shown improved response rates and treatment durations for
many patients with genotype 1 HCV infection. However, persistent
limitations to HCV treatment still exist for patients with prior
treatment failure and comorbid conditions and patients on newer
therapies suffer additional therapy-limiting side effects and drug–drug
interactions. Genetic testing may provide some guidance but additional
options for therapy are still needed for HCV. Many new drugs are
currently under investigation and there is hope that effective and well
tolerated interferon-free regimens may become a part of future therapy.
Introduction
An estimated 130–170 million people are
infected with hepatitis C worldwide leading to significant morbidity,
mortality, and financial burden on healthcare.
[1]
Out of 100 people who contract the infection, 75–85% will develop
chronic infection, 60–70% will develop chronic liver disease, 5–20% will
develop cirrhosis over the course of their chronic infection, and 1–5%
will die of complications including hepatocellular carcinoma (HCC).
[1,2]
The majority of the infected population in the United States, an
estimated 3.2–3.7 million people, are believed to have been born between
1945 and 1965 and likely contracted the virus when transmission rates
were highest in the 1970s and 1980s.
[3,4]
Hepatitis C virus (HCV) has a long and relatively symptom-free
incubation period prior to causing serious illness. Although the
contribution of blood product screening, disposable medical equipment,
and public health education efforts over the years has led to a decrease
in the incidence of HCV in the United States, an estimated 65–75% of
currently infected individuals in the United States are unaware of their
infection. The consequences of these undiagnosed and untreated chronic
infections are expected to be staggering as this population ages with
predictive models suggesting a two-fold increase in HCV-related deaths
with direct medical costs exceeding $6.7 billion between 2010 and 2019
[5]
and, without intervention, a four-fold rise in the incidence of
end-stage liver disease related to hepatitis C within the next 20 years.
[6]
An effort to capture these patients has led to the recent Centers for
Disease Control and Prevention recommendations for birth cohort
screening of the population born between 1945 and 1965 in the United
States.
[4]
Outside of the United States, many other countries worldwide face
significant HCV infection rates. Despite aggressive programs toward
education, care, and treatment over the last 10 years, Egypt faces the
largest burden of HCV infection in the world with a 10% prevalence of
chronic hepatitis C infection among persons aged 15–59 years,
predominantly genotype 4.
[7]
In many parts of the world the virus remains unchecked because of
continued unsafe medical practices, lack of public health education, and
lack of funding for research and treatment. Perz
et al.
[8]
looked at 11 WHO-based regions in 2006 and estimated that globally 27%
of cirrhosis was attributable to HCV and 25% of HCC was attributable to
HCV. In many countries and populations, only a small number of patients
with known infection actually receive treatment and yet successful
treatment has been shown to have a significant impact on outcomes.
[6,9]
A sustained virological response (SVR) to hepatitis C therapy reduces
liver-related as well as all-cause mortality for patients with hepatitis
C
[3,8]
including a 70–80% reduction in overall liver-related mortality and
hepatic decompensation and a 75% reduction in risk of HCC at all stages
of fibrosis.
[4,10]
Until 2011, the historically accepted standard therapy with pegylated
interferon and ribavirin produced an SVR rate of approximately 40–50%
for genotype 1 patients and higher rates up to 80% for alternate
genotypes after 24–48 weeks of therapy.
[11]
The limitations of this therapy are well recognized. Pregnant patients
or those with advanced renal disease are contraindicated from using
ribavirin. Likewise, interferon therapy excludes patients with
autoimmune diseases, uncontrolled depression and mental illness,
decompensated liver disease (child turcotte pugh > 6) or
decompensated cardiac or pulmonary disease. Patients experienced
frequent side effects and those failing therapy due to relapse, non or
null response had few options. This led to aggressive research into
additional treatment targets and ways to predict patient response to
treatment.
Viral Structure
What was first known as non-A, non-B
hepatitis was designated hepatitis C in 1989 by Michael Houghton and
scientists at Chiron Corporation while searching for the blood-borne
cause of hepatitis in transfusion recipients (see Fig. 1).
[12]
Hepatitis C is a single-stranded RNA flavivirus of the hepacivirus
genus. Of the six genotypes, genotype 1 is the most prominent in the
United States and Europe. The virus lacks proofreading ability leading
to significant genetic variation, historically making drug development
against the virus challenging. When the virus enters a liver cell, it
releases its RNA and is translated into a poly-protein containing
structural and nonstructural regions. The poly-protein is processed by
proteases into several polypeptides with different functional roles in
the virus life cycle. The virus is replicated with the help of a
polymerase and then assembled, transported, and released from the cell.
The nonstructural region codes for the polypeptides NS2, NS3, NS4A,
NS4B, NS5A, and NS5B. All are potential targets for drug therapy.
Initial cleavage of the poly-protein is performed by the NS3/NS4A
protease, which seems to be highly conserved across most strains, and,
without which, the HCV life cycle cannot proceed.
[13]
This region became the first therapeutic target for direct-acting
antiviral (DAA) therapy, the NS3/NS4 protease inhibitors telaprevir and
boceprevir.
Viral
structure and genome demonstrating potential therapeutic targets.
Reproduced with permission from.[12] HCV, hepatitis C virus.
The Era of Triple Therapy
The creation of the new standard 'triple
therapy' with the DAA medications has led to significant improvements in
the response rates for patients with genotype 1 HCV, with SVR rates as
high as 63–75% and reduction in duration of therapy by half for many
patients based on response-guided therapy (RGT). The first Food and Drug
Administration (FDA)-approved protease inhibitors, telaprevir and
boceprevir, are designed to mimic the natural NS3/NS4A protease
substrate in genotype 1 HCV, therefore inhibiting the onset of the
replication process. The successes, failures, and new challenges of
triple therapy have become well known. Although the advent of triple
therapy has dramatically improved outcomes for many, therapeutic options
for HCV are still far from optimal. Many new side effects have been
encountered with creative management strategies developed, drug
interactions have taken on new importance and issues with resistance and
intolerance persist. With the explosion of research and development of
newer DAA and additional therapeutic targets, we are at the very
beginning of a new era in HCV therapy. A review of the lessons learned
from the beginning will be important as we move forward.
First-generation Protease Inhibitors: Lessons From Telaprevir and Boceprevir
Telaprevir efficacy was initially proven in
multiple large multicenter trials including protease inhibition for
viral evaluation-1 (PROVE-1), PROVE-2, PROVE-3, ADVANCE, REALIZE, and
illustrating the effects of combinatherapy with telaprevir (ILLUMINATE).
[13–16]
The importance of ribavirin was confirmed by demonstration of
significant viral breakthrough and relapse after therapy in patients in a
pegylated interferon and telaprevir study arm without ribavirin. These
early trials developed and confirmed the utility of RGT, suggesting that
a shortened duration of therapy was acceptable for patients meeting
certain criteria and 24 weeks of telaprevir-based therapy was
noninferior to 48 weeks of triple therapy in patients meeting
appropriate criteria. Differences have been observed in treatment
failure rates between genotypes 1a and 1b and in various
difficult-to-treat groups. African–Americans, those with high-viral
loads, bridging fibrosis or cirrhosis demonstrated somewhat improved
rapid viral response with new agents but responses are still decreased
compared with those observed in naive, noncirrhotic patients.
[14–17]
Conceptually, the Peg-interferon/ribavirin lead-in was introduced to
bring the baseline viral load down prior to starting boceprevir and, in
turn, decrease the emergence of drug-resistant mutations. SVR was
similar in the 28-week and 48-week groups that demonstrated at least a
1.5 log drop in viral load after the 4-week lead-in therapy phase.
Patients in the 28-week triple therapy arm that did not demonstrate the
1.5 log drop after lead-in showed a poor SVR of 30% or less at 28 weeks
compared with the corresponding 48-week group. The overall conclusion
was that RGT based on 4-week lab values would help predict the best
duration of treatment.
[18]
Serine protease inhibitor therapy trial-2 (SPRINT-2) stratified black
and non-black patients into different arms and again demonstrated
persistently lower SVR rates for black patients versus non-blacks,
suggesting interferon resistance continued to play a role.
[19]
Additional studies suggest that the use of interleukin (IL)-28
genotyping (rs 12979860) may also identify patients who are more likely
to qualify for shorter treatment durations in RGT with boceprevir.
[19,20]
Thus, interferon responsiveness is important in prediction of response
to triple therapy; patients with a poor response to interferon might be
best served by waiting for improved future therapies.
Limitations of First-generation Direct-acting Antiviral Therapy
Although the advent of triple therapy with
boceprevir and telaprevir has improved response rates and treatment
durations for many patients with genotype 1 disease, the phase 3
clinical trials demonstrated that many still do not achieve SVR. In
addition, drug–drug interactions limit use, the high pill burden makes
compliance difficult and resistance is still a real threat with unclear
future implications. New rashes and anorectal symptoms are seen with
telaprevir and moderate-to-severe anemia is common in both regimens.
[16,19,21] In December 2012, a black box warning was added to telaprevir labeling in light of some rashes resulting in death.
[22]
What is Needed: Goals for the Future
Traditionally HCV therapy has been
nonspecific in its therapeutic target. Interferon activates the immune
system and inhibits viral replication whereas ribavirin is a nonspecific
antiviral that may inhibit viral replication but also aid in viral
clearance though its true function against HCV is elusive.
[23,24] Newer therapies directed against specific viral and host targets appear to have greater potential for success.
Epidemiologists have produced a long list of
barriers to HCV treatment including goals for future HCV medications
including: improved tolerance, high potency, favorable safety profile,
high barrier to resistance, all oral regimen, pan-genotypic, favorable
pill burden, short duration, few drug interactions, available for
cirrhosis, HIV, mental illness, and affordable.
[5,9] For the first time, ongoing research suggests that many of these goals may be realistic.
Understanding Direct-acting Antiviral Resistance is Important for the Future
Drug resistance was noted in some form with
both telaprevir and boceprevir in the early protease inhibitor trials,
impacting the final structure of treatment protocols. Specifically,
ribavirin use is required by all protocols and genotypic subtypes 1a and
1b demonstrate a recognizable difference in rates of SVR. The findings
are explained by the very low genetic barrier to resistance of protease
inhibitors as a class, defined as the number of amino acid substitutions
required to confer full resistance to a drug.
[25,26]
In general, DAAs with a low genetic barrier to resistance require only
1–2 amino acid substitutions for high resistance and DAAs with a high
barrier to resistance usually require 3–4 amino acid substitutions in
the same region. Telaprevir resistance is recognized to most frequently
be represented by mutation R155K. The R-K change requires only one
nucleotide change in genotype 1a, whereas genotype 1b requires two
nucleotide changes. The amino acid target sequence of the NS3 region
differs significantly between HCV genotypes (explaining why telaprevir
and boceprevir have efficacy limited to genotype 1) and resistance can
develop easily with few mutations.
[25] The barrier to genetic resistance of DAA in development will be a critical factor in the success of future regimens.
Resistance-associated amino acid variants
(RAVs) have been found in treatment-naive HCV as well as after drug
exposure, thought to result from genetic variation inherent in the virus
itself and selective pressure from drugs. Given as monotherapy, most
DAAs rapidly select for HCV variants with reduced drug susceptibility
resulting in virological failure and treatment rebound.
[27]
Although protocols instruct against monotherapy, reaffirmation of the
mandate that these drugs not be used alone is important.
Cross-reactivity has been shown in RAV between telaprevir and boceprevir
and there is the theoretical risk for development of resistance to
several protease inhibitors with injudicious use of one of the current
regimens. Careful monitoring of stopping rules is essential in current
therapies, particularly in the setting of treatment of prior null
responders.
[28]
Fortunately, there are multiple different targets for therapy with
differing genetic barriers to resistance. On the basis of what we have
learned to this point, combination therapy will be the rule in the
future.
New Drugs in Development
In addition to boceprevir and telaprevir, many new DAA and host-targeted drugs are in development
Table 1. New hepatitis C drugs in development
| NS3/4A protease inhibitors | NS5A | NS5B polymerase nucleos(t)ide | NS5B | NNI Host targets |
|---|
| Asunaprevir | Daclatasvir | Mericitabine | Tegobuvir | Alisporovir |
| Vaniprevir | ABT-267 | Sofasbuvir | Filibuvir | Mirvirsen |
| Danoprevir | GS-5885 | IDX184 | BI-207127 |
|
| MK-5172 | PPI-461 | PSI-938 | VX-222 | lambda IFN |
| BI-201335 | BMS791325 | Setrobuvir |
|
|
| Simeprevir |
| ABT-333 |
|
|
| Tibotec | INX-189 |
|
|
|
| ABT-450 |
|
|
|
|
Protease Inhibitors: The Next Generation
Despite their limitations, protease
inhibitors have high antiviral efficacy and will play an important role
in future therapies. Newer protease inhibitors in development:
asunaprevir, danoprevir, vaniprevir, MK-5172, BI-201335, and simeprevir
are expected to have improved tolerance and safety profiles and will
likely be used in combination with pegylated interferon and ribavirin or
in newer DAA combination regimens in the future.
Polymerase Inhibitors: NS5B
Polymerase inhibitors interfere with viral
replication by binding to the NS5B RNA-dependent RNA polymerase. Their
success has been demonstrated extensively in phase 1 and 2 trials, and
they are expected to play an important role in newer DAA combination
therapy regimens. The class comprises two types – nucleos(t)ide
inhibitors and non-nucleotide inhibitors (NNIs). Nucleos(t)ide analogue
inhibitors are active site inhibitors that mimic the natural substrates
of the polymerase, being incorporated into the RNA chain and causing
direct chain termination. As the active site of NS5B is highly
conserved, these are potentially active against all the different
genotypes. In addition, as amino acid substitutions in every position of
the active site may result in loss of function, resistance to
nucleos(t)ide analogue inhibitors is usually low. Mericitabine and
sofosbuvir both have demonstrated convincing data in clinical trials.
Non-nucleoside inhibitors, on the contrary,
bind to several discrete sites outside of the polymerase active center,
which results in a conformational protein change before the elongation
complex is formed – essentially inhibiting the polymerase from a
distance. Resistance is more frequent with NNIs as NS5B is structurally
organized into multiple different domains with at least four different
binding sites. Mutations at the individual binding sites do not
necessarily cause loss of function of the polymerase.
[25] Drugs in this category are tegobuvir, filibuvir, BI-207127, VX-222, ANA598, ABT-333.
NS5A Inhibitors
NS5A is a membrane-associated phosphoprotein
involved in HCV virion production and the viral life cycle. Daclatasvir,
the first in its class NS5A inhibitor, exhibits high potency and is
expected to have a broad range of genotypic coverage; it is synergistic
with other DAAs. Several others are in development including ABT-267,
GS-5885, PPI-461.
[25,28] Host-targeted Therapies
Several drugs are in development against host
targets. Cyclophilin inhibitors such as the cyclophilin A binding
molecule alisporivir appear to have potent anti-HCV activity and have
broad genotype activity for types 1–4. Alisporivir appears to inhibit
HCV viral replication by interfering with the interaction between
cyclophilin A and NS5A. In early trials with pegylated interferon and
ribavirin, an SVR rate into the 70% range was seen with 24 weeks of once
daily therapy and benefits have been confirmed in genotypes 2 and 3,
with particular success against genotype 3 and a very high barrier to
resistance.
[23]
An additional host-targeted agent is the subcutaneously administered
drug, mirvirsen, which specifically targets the liver-specific micro-RNA
miR-122 that is involved in gene expression and HCV viral replication,
producing dramatic suppression of HCV viremia without evidence of RAV or
significant side effects in early trials. New interferons have also
been explored. Native human interferon lambda proteins are generated by
the immune system in response to viral infection. This interferon family
has been found to have antiviral activity against HCV. The interferon
and its receptor are both expressed at high levels by hepatocytes but
not all tissues suggesting that this reagent could have tissue specific
effects, potentially equating to reduced toxicity compared to current
experience with α-interferon.
[23] This could be a better tolerated alternative to interferon α until oral regimens are available.
What About Interferon-free Regimens?
Interferon-free regimens are widely being tested in clinical trials with encouraging results. The following selected trials demonstrate how rapidly progress is being made. Beginning in 2010, studies demonstrated the potential for antiviral efficacy of an all-oral regimen using combinations of drugs with different targets.
Interferon-free regimen for the management of HCV-1 (INFORM-1) was a phase 1 proof of concept study from 2010 using combination DAA without interferon.
[27] Danoprevir, an NS3/4A protease inhibitor, and RG7128 (later named mericitabine), a NS5B nucleoside polymerase inhibitor, were given for up to 13 days in multiple different dosing arms to assess the ability of an interferon-free regimen to suppress viral load. After the treatment period, all patients subsequently were given standard of care pegylated interferon and ribavirin for 48 weeks. Overall, the DAA combination therapy was well tolerated, and there were no treatment-related study withdrawals or dose reductions during the treatment period. Most common adverse event was headache. The DAA combination regimen showed very potent activity against HCV in all participants, including previous null responders giving encouragement that interferon-free all DAA regimens are possible. Of note, patients with cirrhosis were excluded.
SOUND-1 and SOUND-2 trials included an NS3/4A protease inhibitor (BI-201335) and an NNI NS5B polymerase inhibitor (BI-207127) and ribavirin to demonstrate proof of potent antiviral activity against HCV with rapid viral response rates of 73–100% dependent on dosing. Genotype 1b responded more favorably than 1a and the ribavirin-sparing arm in the later trial showed reasonable but substantially lower response rates. Final results were presented in abstract form at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2012.
[29] Patient results were randomized by genotype 1a versus 1b and by IL-28 genotype CC/CT/TT. Ribavirin arms with variable DAA dosing demonstrated a range in SVR12 (SVR after only 12 weeks off therapy), of 52–69% but only 39% in ribavirin-free arms. Genotype 1b responded better than 1a and IL-28 appeared to be an independent predictor of SVR. All IL-28 genotype of 1b and IL-28 CC 1a patients demonstrated SVR 12 rates as high as 84% with the all-oral regimen.
More recently, exciting results from the phase 2 ELECTRON trial were reported.
[30] Sofosbuvir (formerly known as GS-7977) NS5B polymerase inhibitor in a once daily dose was combined with ribavirin for 12 weeks, pegylated interferon and ribavirin for 4, 8, or 12 weeks in naive patients with genotypes 2 or 3 or sofosbuvir monotherapy for 12 weeks in naive patients with genotypes 2 or 3. An additional group of 35 genotype 1 patients was enrolled, 25 naive patients and 10 prior nonresponders who were also treated with sofosbuvir and ribavirin for 12 weeks. After 24 weeks of therapy, all naive genotype 2 and 3 patients on combination therapy had an SVR at 24 weeks (100%). SVR was seen in only 60% of the genotype 2 and 3 patients on monotherapy. Among genotype 1, treatment-naive patients demonstrated 84% SVR and prior nonresponders fared less well with an SVR of only 10%. Sofosbuvir appears to be well tolerated and to have a high barrier to resistance. This study suggests a new DAA option may soon be available for naive patients with genotype 1, 2, and 3; however, ribavirin still plays a role in maintenance of an antiviral response.
[30]
Another new phase 2 clinical trial was found to show even better responses in genotype 1 patients. ABT-450 (an NS3 protease inhibitor) combined with low-dose ritonavir, ABT-333 (a non-nucleoside NS5B polymerase inhibitor), and ribavirin were used in varying doses in treatment-naive and experienced patients excluding those with cirrhosis for 12 weeks. Treatment-naive patients demonstrated an SVR12 of 93–95% depending on dose and treatment experienced patients an SVR12 of 47%. Some viral breakthrough and resistance was noted during treatment in the prior nonresponder population and the study suggests this population will need a modified DAA regimen as extending duration would not have changed outcome. Overall, this 12-week combination therapy may be an effective future therapy for HCV genotype 1.
[31]
Conclusion
We are once again preparing for a dramatic paradigm shift in approach to HCV infection. Worldwide, the epidemic proportions of HCV are coming to light both in the efforts of healthcare workers and governments in the underdeveloped world and in the burden from untreated and undiagnosed disease in the developed world. Numerous new drugs targeting various aspects of the HCV life cycle and the host are in development and clinical trials. Overall, combination therapies will be the rule. New combinations of DAA have synergistic effects, decrease the risk of resistance, and improve antiviral efficacy, are effective in different genotypes and have a favorable safety profile. Despite universal hope for all-oral regimens, pegylated-IFN is still in the literature. Many phase 1 and 2 clinical trials are still designed to demonstrate the safety of new DAA in combination with a pegylated interferon and ribavirin backbone and though the best response rates in interferon containing regimens still tend to be in favorable genotypes or IL-28 CC patients, the important benefit in these combinations is much shorter treatment duration of 12 weeks. Interferon-free combination regimens appear to be on the horizon, providing a new option in particular for patients with non-genotype 1 HCV, but there will still be treatment failures and resistance issues to be overcome, particularly in the treatment experienced population.
http://www.medscape.com/viewarticle/802844_1
